Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found a chemical “signature” in blood-forming stem cells that predicts whether patients with acute myeloid leukemia will respond to chemotherapy. The findings are based on data from nearly 700 AML patients. Read more here.
Study mentioned: Bartholdy B, et al. HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia. J Clin Invest. 2014 Feb 3. pii: 71264. [Epub ahead of print] PMID: 24487588
No comments:
Post a Comment